91 related articles for article (PubMed ID: 18650497)
21. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
23. Orostachys japonicus Suppresses Osteoclast Differentiation by Inhibiting NFATc1 Expression.
Shim KS; Ha H; Kim T; Lee CJ; Ma JY
Am J Chin Med; 2015; 43(5):1013-30. PubMed ID: 26205967
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-124 regulates osteoclast differentiation.
Lee Y; Kim HJ; Park CK; Kim YG; Lee HJ; Kim JY; Kim HH
Bone; 2013 Oct; 56(2):383-9. PubMed ID: 23867221
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
26. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
27. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
28. The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts.
Luchin A; Purdom G; Murphy K; Clark MY; Angel N; Cassady AI; Hume DA; Ostrowski MC
J Bone Miner Res; 2000 Mar; 15(3):451-60. PubMed ID: 10750559
[TBL] [Abstract][Full Text] [Related]
29. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
30. OA10 is a novel p38alpha mitogen-activated protein kinase inhibitor that suppresses osteoclast differentiation and bone resorption.
Jiang T; Qin A; Shao ZY; Tian B; Zhai ZJ; Li HW; Zhu ZA; Dai KR; Ming HZ; Yu YP; Jiang Q
J Cell Biochem; 2014 May; 115(5):959-66. PubMed ID: 24357524
[TBL] [Abstract][Full Text] [Related]
31. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
32. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M
J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084
[TBL] [Abstract][Full Text] [Related]
33. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
[TBL] [Abstract][Full Text] [Related]
34. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
[TBL] [Abstract][Full Text] [Related]
35. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
36. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.
Alatalo SL; Halleen JM; Hentunen TA; Mönkkönen J; Väänänen HK
Clin Chem; 2000 Nov; 46(11):1751-4. PubMed ID: 11067809
[TBL] [Abstract][Full Text] [Related]
37. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
38. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
39. miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration.
Franceschetti T; Kessler CB; Lee SK; Delany AM
J Biol Chem; 2013 Nov; 288(46):33347-60. PubMed ID: 24085298
[TBL] [Abstract][Full Text] [Related]
40. Ca
Liu W; Le CC; Wang D; Ran D; Wang Y; Zhao H; Gu J; Zou H; Yuan Y; Bian J; Liu Z
Toxicology; 2020 Aug; 441():152520. PubMed ID: 32522522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
